{
    "clinical_study": {
        "@rank": "31780", 
        "arm_group": {
            "arm_group_label": "Subsys"
        }, 
        "brief_summary": {
            "textblock": "Chronic pain patients who experience breakthrough pain in the background of controlled\n      persistent pain with opioids will be followed for 3 months in order to assess the safety and\n      titration trends in the clinical practice setting of a novel fentanyl sublingual spray\n      (Subsys\u2122) for the treatment of breakthrough pain."
        }, 
        "brief_title": "An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys\u2122 Spray.", 
        "condition": "Breakthrough Pain", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Patients \u2265 18 years of age.\n\n          -  Subjects who are experiencing 1-4 episodes of break through pain per day in spite of\n             optimized background analgesia and who have taken at least 60 mg/day of morphine (or\n             equivalent analgesic) for at least 7 days.\n\n          -  Who are currently using Actiq\u00ae for their breakthrough pain and are being discontinued\n             due to lack of efficacy, side effects, patient dissatisfaction or prescriber\n             dissatisfaction with treatment.\n\n          -  Are able to follow and complete all necessary study procedures.\n\n          -  Are willing and able to give written informed consent before participating in the\n             study.\n\n          -  Enrolled in the class wide REMS as verified by the study personnel.\n\n        Exclusion Criteria:\n\n          -  Subjects who are not opioid tolerant.\n\n          -  Using a rapid onset opioid other than Actiq\u00ae to manage their breakthrough pain.\n\n          -  Have physical abnormalities of the floor of the mouth that could affect absorption as\n             determined by investigator.\n\n          -  Are subjects with uncontrolled or rapidly escalating pain.\n\n          -  Are subjects with a history of alcohol or substance abuse within the last 3 years.\n\n          -  Have a clinically significant medical history (past or present) of any disease that\n             would compromise the study or the well-being of the subject.\n\n          -  Are subjects who have participated in another clinical trial with an analgesic within\n             the last month.\n\n          -  Are female subjects with a positive pregnancy test or who are currently lactating.\n\n          -  Are subjects who are taking medications that are known inhibitors of the CYP3A4\n             isozyme, such as ketoconazole.\n\n          -  Are subjects who have taken a monoamine inhibitor within 14 days before a dose of\n             study medication.\n\n          -  Opioid being used for chronic migraine or acute pain.\n\n          -  Are subjects who are unsuitable for inclusion for any other reason, in the opinion of\n             the investigator."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Chronic pain patients who are opioid tolerant and who have failed Actiq\u00ae therapy for their\n        breathrough pain will be prescribed Subsys\u2122 fentanyl sublingual spray for their\n        breakthrough pain."
            }
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 25, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01901718", 
            "org_study_id": "ICRI-Subsys-001"
        }, 
        "intervention": {
            "arm_group_label": "Subsys", 
            "intervention_name": "Subsys", 
            "intervention_type": "Drug", 
            "other_name": "Fentanyl Sublingual Spray"
        }, 
        "intervention_browse": {
            "mesh_term": "Fentanyl"
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breakthrough Pain", 
            "Subsys", 
            "Fentanyl", 
            "Opioid", 
            "Persistent Pain"
        ], 
        "lastchanged_date": "August 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Overland Park", 
                    "country": "United States", 
                    "state": "Kansas", 
                    "zip": "66210"
                }, 
                "name": "International Clinical Research Institute"
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "1", 
        "official_title": "An Observational, Non-Interventional Trial to Assess Patient Satisfaction and Safety of Subsys\u2122 Spray Compared to Actiq\u00ae for the Management of Breakthrough Pain in Chronic Pain Patients.", 
        "other_outcome": {
            "description": "Time to \"optimal\" dose of an open-label study medication in the Titration phase.", 
            "measure": "Optimal Dose Calculation", 
            "safety_issue": "No", 
            "time_frame": "14 Days"
        }, 
        "overall_official": {
            "affiliation": "International Clinical Research Institute", 
            "last_name": "Srinivas Nalamachu, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "United States: Institutional Review Board", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "November 2013", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The overall impression of change based on a patient's response to the Patient Global Impression of Change (PGIC) questionnaire at month 1, 2, and 3 or upon early discontinuation.", 
            "measure": "Patient Global Impression of Change", 
            "safety_issue": "No", 
            "time_frame": "30, 60, 90 days"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01901718"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "Patients will rate their treatment satisfaction using a 5-point scale ranging from 1= Very Dissatisfied to 5= Very Satisfied.", 
                "measure": "Percent of Patients Satisfied with Treatment", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30, 60, 90 days"
            }, 
            {
                "measure": "Study Medication Ease of Use", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30, 60, 90 days"
            }, 
            {
                "description": "Short Form 12 Question Health Survey Version 2 (SF-12v2) will be used to assess a subject's general quality of life.", 
                "measure": "Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30, 60, 90 days"
            }, 
            {
                "description": "Medical Outcomes Score (MOS) Sleep Subscale will be used to measures 6 dimensions of sleep and is a useful indicator of the efficacy of analgesic medications.", 
                "measure": "Assessment of Sleep", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30, 60, 90 days"
            }, 
            {
                "description": "Equianalgesic dosing will be calculated based on subject's prior dose of Actiq\u00ae and final effective dose of Subsys\u2122.", 
                "measure": "Medication Dosing", 
                "safety_issue": "No", 
                "time_frame": "Baseline"
            }, 
            {
                "measure": "Weight", 
                "safety_issue": "No", 
                "time_frame": "Baseline, 30, 60, 90 days"
            }, 
            {
                "description": "Blood will be drawn to measure HbA1c.", 
                "measure": "Blood Glucose", 
                "safety_issue": "No", 
                "time_frame": "Baseline and 90 days"
            }
        ], 
        "source": "International Clinical Research Institute", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "International Clinical Research Institute", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2013", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "August 2013"
    }
}